NEW YORK (GenomeWeb News) – OpGen has raised $2.1 million, the Gaithersburg, Md., firm confirmed today.
The raise, which OpGen disclosed in a document filed with the US Securities and Exchange Commission on Friday, is bridge financing and will be used to support the commercialization of its flagship technology, the Argus Optical Mapping System, a company spokesman told GenomeWeb Daily News today.
The platform was launched last year. In its filing, the company said it is targeting $2.3 million in the round.
OpGen's platform uses optical mapping technology for whole-genome sequence assembly and finishing. The company, founded in 2002, is seeking to commercialize products and services based on its technologies "for high-precision microbial analysis as well as human, animal, and plant genome sequencing," the spokesman said.
There were 27 participants in the round, including "significant" existing investors.
The molecular diagnostics firm raised $20 million in a Series B round earlier this year.